October 4, 2016 06:01 PM EDT
R&D
Pharma

No­var­tis is up­root­ing an­oth­er re­search group in on­go­ing glob­al re­or­ga­ni­za­tion

John Carroll

Editor & Founder

The globe trot­ting chief of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search turned up in Sin­ga­pore this week with some bad news for the 85 staffers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times